Ignota Labs, a Cambridge, UK-based AI-driven drug turnaround company, raised USD 6.9M in Seed funding.
The round was led by Montage Ventures and AIX Ventures with participation from Modi Ventures, Blue Wire Capital, and Gaingels.
The company intends to use the funds to expand the pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of their first asset, a PDE9A inhibitor.
Led by CEO Sam Windsor, Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects for patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering USD 400 billion annual loss and delaying life-saving treatments for patients. Its proprietary platform, SAFEPATH, uses deep learning to address these challenges by uncovering the mechanisms behind drug toxicity, combining cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates.
Ignota Labs is building a pipeline to bring drugs to market faster, partnering to develop and co-develop assets that might otherwise fail, and accelerating the delivery of vital therapies to patients in need.
FinSMEs
26/02/2025